Dana-Farber Cancer Institute | Strategic Alliance Partners

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.

The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

An overview of ongoing research in the endometrial cancer treatment space.

Paolo Tarantino, MD, discusses how the ongoing shortages of carboplatin and cisplatin in the United States are affecting patients with breast cancer and the importance of overcoming this wave of shortages and preventing this issue from recurring in the future.

Pasi A. Jänne, MD, PhD, discusses key trials evaluating the efficacy of single-agent osimertinib in patients with metastatic EGFR-mutated non–small cell lung cancer.

After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.

Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.

Nancy U. Lin, MD, discusses selecting between systemic vs local therapy for patients with HER2-positive breast cancer displaying central nervous system metastases.

Jacob Sands, MD, discusses how the ongoing shortages of carboplatin and cisplatin have presented new challenges to patient care, how he and colleagues at Dana-Farber Cancer Institute are navigating these shortages, and how these limitations could ultimately have an impact on patients.

Dr. Gooptu explains the risk factors associated with both acute and chronic GVHD.

Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.

A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.

Eno-Abasi Inyang, PharmD, BCPS, BCOP provides an overview of the various conditioning regimens employed for allogeneic stem cell transplantation.

Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.

A panel of gynecologic oncologists review the PHAEDRA study and discuss the overall treatment landscape for endometrial cancer.

Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.

Maxine Sun, PhD, MPH, discusses ongoing research efforts dedicated to examining the relationship between clonal hematopoiesis and cardiovascular disease in patients with renal cell carcinoma.

Researchers in the Bernstein Laboratory at Dana-Farber and the Broad Institute of MIT and Harvard have found that gliomas– incurable brain tumors– can arise due to changes in the epigenome.

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.

Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.

Adrienne G. Waks, MD, discusses treatment alternatives in the third line and beyond for patients with metastatic HER2-positive breast cancer.

Paolo Tarantino, MD, discusses the evolution and impact of the continued investigation of antibody-drug conjugates in the treatment of patients with hormone receptor–positive breast cancer.

Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.

Experts on endometrial cancer review the NRG-GY018 and RUBY clinical trials.

The expert panel switches its focus to endometrial cancer and discusses recent data from clinical trials.

Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.

As new data emerge in breast cancer, stepping back from the updates and shedding light on the standard practices as they exist in the clinic are crucial approaches to management of the disease.

A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.